<span item_type="fundamental" item_id="f7cd0b3f9c75d0aac7b4c4b1661e41f0" counter_id="ST/US/CBGGF" env="prod"></span><span item_type="announcement" item_id="538780666795399041" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.06.</p><p></p><h3>Segment Revenue</h3><ul><li>The company did not generate any operating revenues for the three months ended March 31, 2025, as it is a blank check company focused on finding a business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The company reported a net loss of $363,640 for the three months ended March 31, 2025, compared to a net loss of $1,238,211 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li><li><strong>General and Administrative Expenses</strong>: These expenses were $191,850 for the three months ended March 31, 2025, down from $510,056 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li><li><strong>Change in Fair Value of Derivative Liabilities</strong>: The company recorded a gain of $187,430 from the change in fair value of derivative liabilities for the three months ended March 31, 2025, compared to a loss of $990,040 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: The company used $72,033 in net cash for operating activities for the three months ended March 31, 2025, compared to $149,102 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li><li><strong>Net Cash Used in Financing Activities</strong>: The company used $26,328 in net cash for financing activities for the three months ended March 31, 2025, compared to $34,357,416 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Income from Investments Held in Trust Account</strong>: The company earned $55,415 from investments held in the Trust Account for the three months ended March 31, 2025, compared to $343,520 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company has until November 15, 2025, to consummate an initial business combination. If not completed by this date, the company must cease operations, redeem public shares, and liquidate.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li><li><strong>Non-Core Business</strong>: The company terminated its business combination agreement with Phytanix Bio on April 7, 2025, and is seeking other potential business combinations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025064429/ea0248893-10q_chain1.htm"></span></li></ul>

CHAIN BRIDGE I UNIT 1 CL A & 1/2 RED WT EXP(15/11/2024) | 10-Q: FY2025 Q1 EPS: USD -0.06